Lamivudine 100mg (Generic)

Product Overview

Lamivudine 100mg is a generic antiviral tablet produced by Cipla Limited, a pharmaceutical company with a global footprint in the manufacturing of high‑quality medicines. Each strip contains ten film‑coated tablets, each delivering exactly 100 mg of the active ingredient lamivudine. The product is marketed in three pack sizes—30, 60, and 90 tablets—allowing patients and healthcare providers to select the most appropriate supply for chronic treatment courses. This medication is indicated for two major therapeutic areas: chronic hepatitis B virus (HBV) infection and as part of combination antiretroviral therapy for human immunodeficiency virus (HIV) infection. The tablets are designed for oral administration and are packaged to protect the drug from moisture and light, ensuring stability throughout the shelf life.

What is Lamivudine 100mg

Lamivudine belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs), a group of compounds that mimic the natural building blocks of viral DNA. The active moiety, lamivudine, is a synthetic analog of cytidine that, once inside an infected cell, is phosphorylated to its triphosphate form. This phosphorylated form interferes with the viral reverse transcriptase enzyme, the protein responsible for converting viral RNA into DNA during replication. Because the analog lacks a 3′‑hydroxyl group, its incorporation terminates the growing viral DNA chain, effectively halting further replication. The 100 mg strength represents the standard adult dosage used in most clinical protocols for both HBV and HIV, and the formulation is fully bioequivalent to the reference brand product. For additional details, see Wikipedia.

Uses and Benefits

The therapeutic uses of Lamivudine 100mg extend to two distinct but related disease states. In chronic hepatitis B, long‑term treatment with lamivudine can reduce serum ALT and AST levels, improve histologic activity, and decrease the risk of cirrhosis and hepatocellular carcinoma when adherence is maintained. For patients living with HIV, lamivudine provides potent suppression of viral replication when combined with other antiretroviral agents, helping to preserve CD4+ T‑cell counts and delay the onset of opportunistic infections. Clinical trial data have shown that patients receiving lamivudine experience a slower rate of disease progression compared with placebo, and the drug is generally well tolerated when used according to recommended regimens.

How It Works

The mechanism of action of lamivudine is rooted in its structural similarity to cytidine, one of the four nucleotides that compose RNA and DNA. After oral ingestion, lamivudine is absorbed in the gastrointestinal tract and undergoes intracellular phosphorylation to form lamivudine‑5′‑triphosphate (L‑TP). L‑TP competes with natural cytidine triphosphate (CTP) for incorporation into the viral DNA strand synthesized by reverse transcriptase. Because the molecule is missing a 3′‑hydroxyl group, each incorporation event stops further chain elongation, leading to premature termination of viral DNA synthesis. This process reduces the viral load in the bloodstream, alleviates liver inflammation in HBV infection, and supports immune function in HIV‑infected individuals.

Dosage Guidelines

Dosage of Lamivudine 100mg should always be individualized by a qualified healthcare professional based on the patient’s clinical status, renal function, and concomitant medications. The usual adult dose for chronic hepatitis B is one tablet daily, taken at the same time each day, with or without food. In patients with severe renal impairment—defined as a creatinine clearance below 30 mL/min—clinical guidelines recommend a reduced dose, often 100 mg every other day, to prevent accumulation of the drug and its metabolites. When lamivudine is used as part of an HIV regimen, the standard dosage is also 100 mg once daily, but it is typically paired with other antiretroviral classes to minimize the emergence of resistance. Patients are advised to maintain consistent dosing, avoid missed doses, and to discuss any dose adjustments with their prescribing clinician before implementation.

Side Effects

Like all pharmaceutical agents, Lamivudine 100mg may produce adverse effects, although many are mild and transient. The most frequently reported side effects include gastrointestinal disturbances such as nausea, vomiting, or abdominal discomfort, as well as headache and mild fatigue. Less common but clinically important events can involve peripheral neuropathy, characterized by tingling or numbness in the extremities, and elevations in liver enzymes that may indicate hepatic stress. Rare but serious complications include lactic acidosis—a potentially life‑threatening metabolic disturbance—and severe hepatic injury, which require immediate discontinuation of the drug and urgent medical evaluation. Patients should be instructed to report any new or worsening symptoms, particularly signs of liver dysfunction such as jaundice, dark urine, or unexplained bruising.

Warnings and Precautions

Before initiating therapy, clinicians should perform a thorough assessment of renal function, hepatitis B e‑antigen (HBeAg) status, and potential drug interactions. Resistance to lamivudine can develop rapidly if the medication is used as monotherapy for HIV; therefore, it is recommended to combine lamivudine with at least two other active antiretroviral agents to preserve efficacy. Pregnant or lactating women should only use lamivudine when the anticipated benefit justifies the potential risk, and dosage may need modification as pregnancy progresses. Patients with a history of pancreatitis, severe hepatic disease, or those taking other nephrotoxic medications should be monitored closely with periodic laboratory tests. Proper storage in a dry, temperature‑controlled environment and keeping the medication out of reach of children are essential safety practices. For detailed drug interaction guidance, refer to the NIH.

Storage and Handling

Lamivudine 100mg tablets should be stored at room temperature, away from excessive heat and moisture. Keep the medication in its original packaging until ready to use, and ensure the strip is sealed to protect the tablets from humidity. Do not use the medication past the expiration date printed on the label. If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed. It is important never to double up on doses to compensate for a missed one.

FAQs

Q: What distinguishes Lamivudine 100mg from other hepatitis B therapies such as entecavir or tenofovir?
A: Lamivudine acts as a nucleoside analog that inhibits viral reverse transcriptase, whereas entecavir and tenofovir target different stages of the HBV replication cycle. The selection among these agents depends on factors such as resistance profile, co‑infected status, and patient‑specific tolerability.

Q: Can Lamivudine 100mg be used alone for HIV treatment?
A: No. Monotherapy with lamivudine for HIV is not recommended because it promotes the development of resistant viral strains. It must be combined with other antiretroviral drugs to achieve durable viral suppression.

Q: How quickly does Lamivudine 100mg lower viral load?
A: The reduction in viral load can be detected within a few weeks of consistent dosing, though the exact speed and magnitude depend on baseline viral load, adherence, and the presence of other co‑administered agents.

Q: Is dose adjustment necessary for patients with kidney disease?
A: Yes. Lamivudine is primarily excreted unchanged through the kidneys. In patients with a creatinine clearance below 30 mL/min, a reduced dosing interval (e.g., every other day) is advised to avoid drug accumulation and potential toxicity.

Q: Where can I find the full prescribing information for Lamivudine 100mg?
A: Detailed prescribing details are available on the official FDA label (FDA) and on MedlinePlus (MedlinePlus). These resources provide comprehensive guidance on indications, contraindications, and safety considerations.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)